Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [916]
News [2620]
Articles [112]
Editorials [3]
Conferences [85]
elearning [27]
Precision medicine in ALK-positive NSCLC: Results from the BFAST trial
Prof Solange Peters and Prof Tony Mok
Precision medicine in ALK-positive NSCLC: Results from the BFAST trial ( Prof Solange Peters and Prof Tony Mok )
3 Oct 2019
Comment: Nivolumab plus ipilimumab combination for advanced NSCLC
Dr Marina Garassino - National Tumor Institute, Milan, Italy
Comment: Nivolumab plus ipilimumab combination for advanced NSCLC ( Dr Marina Garassino - National Tumor Institute, Milan, Italy )
28 Sep 2019
Comment: Osimertinib for EGFR-mutation positive NSCLC
Dr Pilar Garrido - University Hospital Ramón y Cajal, Madrid, Spain
Comment: Osimertinib for EGFR-mutation positive NSCLC ( Dr Pilar Garrido - University Hospital Ramón y Cajal, Madrid, Spain )
28 Sep 2019
Nivolumab plus ipilimumab combination offers chemotherapy-free option for...
Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne...
Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLC ( Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland )
28 Sep 2019
Front-line osimertinib significantly lengthens overall survival in EGFR...
Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta...
Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA )
28 Sep 2019
Comment: Immunotherapy combination for advanced NSCLC
Dr Marina Garassino - National Tumour Institute, Milan, Italy
Comment: Immunotherapy combination for advanced NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )
28 Sep 2019
Comment: Front-line osimertinib significantly lengthens overall survival in...
Dr Marina Garassino - National Tumour Institute, Milan, Italy
Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )
28 Sep 2019
Important developments in radiation oncology
Dr Ana Botero - Memorial Healthcare System, Hollywood, FL, USA
Important developments in radiation oncology ( Dr Ana Botero - Memorial Healthcare System, Hollywood, FL, USA )
26 Jul 2019
New standard of care for lung cancer patients with EGFR mutations
Dr Gelenis Domingo - Memorial Healthcare System, Hollywood, FL, USA
New standard of care for lung cancer patients with EGFR mutations ( Dr Gelenis Domingo - Memorial Healthcare System, Hollywood, FL, USA )
26 Jul 2019
Lung cancer screening and the management of the pulmonary nodule
Dr Mark Block - Memorial Healthcare System, Hollywood, FL, USA
Lung cancer screening and the management of the pulmonary nodule ( Dr Mark Block - Memorial Healthcare System, Hollywood, FL, USA )
26 Jul 2019
Immunotherapy for lung cancer before surgery
Dr. Luis Raez - Memorial Cancer Institute, Florida, USA
Immunotherapy for lung cancer before surgery ( Dr. Luis Raez - Memorial Cancer Institute, Florida, USA )
19 Jul 2019
SPRING 01: Exploring the combination of avelumab, axitinib and palbociclib in...
Dr Benjamin M. Solomon - Avera Cancer Institute, Sioux Falls, USA
SPRING 01: Exploring the combination of avelumab, axitinib and palbociclib in patients with advanced metastatic NSCLC ( Dr Benjamin M. Solomon - Avera Cancer Institute, Sioux Falls, USA )
10 Jul 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation